Wed, Apr 16, 2014, 9:50 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

  • druggy62 druggy62 Feb 8, 2013 5:18 PM Flag

    Valuation Comparisons

    Let's use Titan for example:

    TTNP:
    Market size for product: $1.5 billion
    Estimated peak sales: $500 million
    Market cap: $160 million

    KERX:
    Market size for product: $1.5 billion
    Estimated peak sales: $600 million
    Market cap: $480 million

    TTNP already has a PDUFA date and a partner.
    If KERX is so undervalued, than TTNP is triply undervalued.
    Or KERX is grossly overvalued.
    Which is it?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ok Einstein let me explain to you why that OTC board junk you're pumping is worth so little...
      the peak sales for Probuphine is in 300M-500M and all TTNP will get out of this is double digit royalty, you know what that means?...10%-12% most likely..now do the math..in the best case scenario Titan will have just 30M to 50M annual income from this drug...I say 160M cap is pretty generous already..so, get lost

      • 1 Reply to a_gasparyan
      • Who the F gives what exchange a company is listed on in a valuation comparison?
        10% to 12%, try 20% to 25%.

        Hey genius, will KERX go it alone against Sanofi and Shire?
        When they partner, don't you think that they will get a royalty too?

        OK, so lets use your 10% to 12% royalty for KERX.
        What would their income be? $60M to $70M?
        How does your $480M market cap look then?

        We don't have to use TTNP in the comparison.
        Wanna try another? POZN, DEPO, PATH?

        So you take a hike, obnoxious twit.
        You think you know it all, but you have a lot to learn.

 
KERX
13.92+0.01(+0.07%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.